These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264 [TBL] [Abstract][Full Text] [Related]
43. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088 [TBL] [Abstract][Full Text] [Related]
44. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]. Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201 [TBL] [Abstract][Full Text] [Related]
45. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma. Roncati L Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488 [TBL] [Abstract][Full Text] [Related]
47. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer. Lin H; Wu Y; Chen J; Huang S; Wang Y Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658 [TBL] [Abstract][Full Text] [Related]
49. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
50. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933 [TBL] [Abstract][Full Text] [Related]
51. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989 [TBL] [Abstract][Full Text] [Related]
53. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162 [TBL] [Abstract][Full Text] [Related]
54. Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression? Saleh K; Khalifeh-Saleh N; Kourie HR Immunotherapy; 2018 Apr; 10(5):345-347. PubMed ID: 29473468 [No Abstract] [Full Text] [Related]
55. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883 [TBL] [Abstract][Full Text] [Related]
57. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma? Ansell SM J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644 [TBL] [Abstract][Full Text] [Related]
58. [PD-1 blockade therapy in lymphoid malignancies]. Nishikori M; Takaori-Kondo A Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847 [TBL] [Abstract][Full Text] [Related]
59. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553 [TBL] [Abstract][Full Text] [Related]
60. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade. Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]